deutaleglitazar

Deutaleglitazar (AB-101) is a deuterated small molecule dual agonist of peroxisome proliferator-activated receptors alpha (PPARα) and gamma (PPARγ). Developed by Alebund Pharmaceuticals, it is a deuterated analog of aleglitazar, a compound originally developed for type 2 diabetes and cardiovascular disease. The incorporation of deuterium is intended to enhance the metabolic profile and safety of the drug by reducing the formation of toxic metabolites or slowing clearance. Deutaleglitazar is currently being evaluated in Phase II clinical trials for the treatment of chronic kidney diseases, specifically diabetic kidney disease (DKD) and IgA nephropathy (IgAN), where it is expected to provide renal protection through its effects on lipid metabolism, insulin sensitivity, and inflammation.

Other names

deutaleglitazarAB-101AB101AB 101deuterated aleglitazar